Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney, and thyroid cancers using its investigational therapy LP-184 (zirdafulven). The allowed claims are based on a three-gene biomarker signature comprising elevated expression of PTGR1, PTPN14, and ASPH, which identifies patients likely to benefit from LP-184 treatment.
The company's RADR artificial intelligence platform played a key role in identifying this biomarker signature, supporting a precision medicine approach for LP-184. According to Lantern, its Phase 1a trial demonstrated a 45% disease control rate among patients treated at or above the effective therapeutic dose. The company plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio.
The full press release is available at https://ibn.fm/LRGUo.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform cancer therapy development. Its clinical pipeline includes LP-184, LP-284 (a TC-NER targeting compound for hematologic and solid tumors), and LP-300 (a cisplatin/ethacraplatin analog), the latter being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma after TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
Additionally, Lantern’s multi-agentic AI co-scientist platform, withZeta.ai, is now commercially available as a subscription-based research platform for the global biomedical community, representing a new revenue stream. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
Investors can find the latest news and updates relating to LTRN in the company’s newsroom at https://ibn.fm/LTRN.
